Detail akcie ACADIA Pharm online

Business Summary: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.
Financial Summary: BRIEF: For the six months ended 30 June 2025, ACADIA Pharmaceuticals Inc revenues increased 14% to $508.9M. Net income decreased 9% to $45.7M. Revenues reflect NUPLAZID segment increase of 14% to $328.2M, DAYBUE segment increase of 13% to $180.7M. Net income was offset by General And Administrative Expencess increase of 19% to $242.4M (expense), Other Research and development increase of 16% to $148.3M (expense).